Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Analytical Decisions on Physical Activity Outcomes in a Cardiovascular Mobile Health Study.

Journal of the American Heart Association·2026
Same author

The Role of Implicit Bias in Shaping Medication Prescribing Practices: A Scoping Review.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

The impact of data source on real-world medication adherence and exposure measures: From prescription to sold.

Journal of managed care & specialty pharmacy·2026
Same author

Rapid quantitative urinary chloride sensing with conductivity correction for cardiac patient management.

Biosensors & bioelectronics·2026
Same author

Patient and Clinician Attitudes Toward Mobile Health Apps: Qualitative Study.

JMIR mHealth and uHealth·2026
Same author

Evaluating patient acceptability of clinical pharmacist engagement following clinical decision support.

Exploratory research in clinical and social pharmacy·2026

Related Experiment Video

Updated: Jun 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Factors associated with clopidogrel nonresponsiveness.

Kathryn M Momary1, Michael P Dorsch

  • 1Mercer University College of Pharmacy and Health Sciences, Department of Pharmacy Practice, 3001 Mercer University Drive, Atlanta, GA 30341, USA. momary_km@mercer.edu

Future Cardiology
|March 17, 2010
PubMed
Summary

Clopidogrel responsiveness varies significantly due to genetic factors and drug interactions affecting its metabolism. Understanding these factors is crucial for effective antiplatelet therapy and preventing adverse cardiovascular events.

Related Experiment Videos

Last Updated: Jun 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Genetics

Background:

  • Clopidogrel is a standard antiplatelet therapy for acute coronary syndrome and percutaneous coronary intervention.
  • Significant interindividual variability exists in patient response to clopidogrel.
  • Clopidogrel is a prodrug requiring metabolism by CYP450 enzymes for its antiplatelet effect.

Purpose of the Study:

  • To review genetic polymorphisms and drug interactions affecting CYP450 enzymes and clopidogrel responsiveness.
  • To examine clinical factors influencing clopidogrel response and associated cardiovascular risks.
  • To highlight the importance of recognizing all causes of clopidogrel nonresponsiveness.

Main Methods:

  • Review of literature on genetic variations in CYP450 enzymes (e.g., CYP2C19).
  • Analysis of drug interactions, particularly with proton pump inhibitors.
  • Examination of clinical factors impacting clopidogrel pharmacokinetics and pharmacodynamics.

Main Results:

  • Genetic polymorphisms in CYP450 enzymes, especially CYP2C19, are a primary cause of clopidogrel nonresponsiveness.
  • Drug interactions, notably with proton pump inhibitors, can impair clopidogrel activation.
  • Clinical factors also contribute to variable patient response and increased adverse cardiovascular events.

Conclusions:

  • Understanding genetic and drug interaction-related clopidogrel nonresponsiveness is vital for clinicians.
  • Recognizing all factors influencing clopidogrel response is essential, especially with emerging antiplatelet alternatives.
  • Optimizing clopidogrel therapy requires consideration of individual patient factors and potential interactions.